Rheumatoid Arthritis

Gary S. Firestein, Gabriel Panayi, Frank Wollheim (Herausgeber)

Buch | Hardcover

594 Seiten

2006 | 2nd Revised edition
Oxford University Press (Verlag)
978-0-19-856630-4 (ISBN)

Titel ist leider vergriffen;
keine Neuauflage

Artikel merken

This book describes the latest advances in our understanding of this common, crippling disease and relates this knowledge to the application of a more rational therapeutic approach to its management. The book covers the scientific basis of the pathogenesis of rheumatoid arthritis and the rationale for the treatment, both drug and non-drug, of the disease

Rheumatoid arthritis (RA) is a chronic inflammatory disease, which affects 1% of the world's population. Patients with RA not only have a progressive and debilitating disease and severe functional impairment, but can also experience a reduced life expectancy due to frequent involvement of the major organ systems. This new edition of Rheumatoid Arthritis charts the profound changes in research and patient management that have taken place over the last 5 years.
Developments in molecular biology have dramatically increased insight into the inflammatory and destructive pathways of this complex disease. Over half a million patients have been successfully treated with biologic therapy and advances in imaging techniques have allowed increasingly early detection of
disease onset. Rheumatoid factor is no longer the unchallenged gold standard autoantibody but has competition from the anti-citrulline antibodies. Environmental factors influencing both susceptibility and progression have been sought, and smoking has emerged as a powerful factor. Steady progress in genetics is finally being made and one day it may be possible to predict RA before onset of symptomatic disease.

It is against this backdrop of dynamic developments that the new edition of Rheumatoid Arthritis publishes.

Preface ; SECTION 1 ; Etiology ; 1. Genetics of rheumatoid arthritis ; 2. Epidemiology and determinants of susceptibility ; 3. Microbes in the pathogenesis of rheumatoid arthritis ; 4. Experimental models for rheumatoid arthritis ; SECTION 2 ; Mechanisms of inflammation ; 5. The role of macrophages in rheumatoid arthitis ; 6. The role of T lymphocytes in rheumatoid arthritis ; 7. The role of neutrophils in the pathogenesis of rheumatoid arthritis ; 8. The role of fibroblast-like synoviocytes in rheumatoid arthritis ; 9. The roles of B cells in rheumatoid arthritis ; 10. Innate immunity and immune complexes in rheumatoid arthritis ; 11. Angiogenesis and cell trafficking ; 12. Cytokine networks ; 13. Autoantibodies in rheumatoid arthritis ; 14. Mechanisms of fibroblast-mediated joint destruction ; 15. Pain mechanisms in rheumatoid arthritis ; 16. The stress system and the hypothalamic-pituitary adrenal (HPA) axis in rheumatoid arthritis ; SECTION 3 ; Clinical Aspects ; 17. Examination of the synovium and synovial fluid ; 18. Clinical aspects of rheumatoid arthritis ; 19. Imaging in rheumatoid arthritis ; 20. Susceptibility, prognosis & mortality ; 21. Biomarkers for cartilage and bone in rheumatoid arthritis ; SECTION 4 ; Drug Therapy ; 22. NSAIDS and analgesics ; 23. Systemic and intra-articular glucorticoids in rheumatoid arthritis ; 24. Methotrexate and Leflunomide ; 25. Gold, antimalarials, sulfasalazine, and other DMARDS ; 26. Combination therapy with synthetic DMARDs in the treatment of rheumatoid arthritis ; 27. Biologics in the treatment of rheumatoid arthritis ; SECTION 5 ; Non-Drug Therapy ; 28. The impact of physiotherapy ; 29. Patient Education ; 30. Occupation therapy and assistive products and technology ; 31. Psychological and social aspects ; 32. Pain management ; 33. Health economics ; SECTION 6 ; Surgical Therapy ; 34. Large joints and feet ; 35. The hand ; 36. The cervical spine ; SECTION 7 ; Frontiers of Therapy ; 37. Design of trials involving clinical endpoints ; 38. Clinical trials with imaging and biomark endpoints ; 39. New biologics: cytokines ; 40. New biologics: T and B cell modulators ; 41. Inhibibition of proteolytic activity involved in cartilage breakdown ; 42. Signal transduction in rheumatic diseases ; 43. Mesenchymal stem cells in arthritis

Erscheint lt. Verlag	20.7.2006
Zusatzinfo	8 pp colour plate section + 220 b&w illustrations
Verlagsort	Oxford
Sprache	englisch
Maße	227 x 284 mm
Gewicht	1985 g
Themenwelt	Medizinische Fachgebiete ► Innere Medizin ► Rheumatologie
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Orthopädie
ISBN-10	0-19-856630-1 / 0198566301
ISBN-13	978-0-19-856630-4 / 9780198566304
Zustand	Neuware